BBCA Pharmaceuticals is constituted of three systems which are pharmaceutical R&D, production, and sale. It has 5 pharmaceutical plants and 45 GMP certified production line, mainly involving R&D, production and sale of biological pharmacy, chemical pharmacy, and traditional Chinese medicine, and possessing nine classes of products including antipyretic-analgesic drug, cardiovascular drug, antibiotic, nervous system drug, anti-tumor drug, antiulcer drug, hormones drug, nutriceutical, and preparation of traditional Chinese medicine, etc. BBCA Pharmaceuticals can produce 11 kinds of dosage form, including large-volume injection, small-volume injection, powder injection, capsules, powders, tablets, granules, films, eye drops, patches, etc, 395 varieties, as well as many kinds of material drugs. There are more than 40 varieties of national new drugs being researched and developed, some of which have come into the market. BBCA Pharmaceuticals has many varieties of the first and second national new medicine and has the independent intellectual property of the products and various production technologies. While pursuing scale and series production. BBCA carried out the strategy of omnidirectional market cultivation and development. It has set up the sales offices in more than 30 provinces, municipalities and autonomous regions all over the country. Depending on BBCA advanced technology and abundant strength, BBCA Pharm exports products to all over the world, including Europe, North America, Africa, Southeast Asia and Central Asia.